Sfoglia per Autore
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models
2021 Sharma, G; Arosio, G; Villa, M; Mauri, M; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Crespiatico, I; Fontana, D; Mastini, C; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
2021 Lobello, C; Tichy, B; Bystry, V; Radova, L; Filip, D; Mraz, M; Montes-Mojarro, I; Prokoph, N; Larose, H; Liang, H; Sharma, G; Mologni, L; Belada, D; Kamaradova, K; Fend, F; Gambacorti Passerini, C; Merkel, O; Turner, S; Janikova, A; Pospisilova, S
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome
2021 Banfi, F; Rubio, A; Zaghi, M; Massimino, L; Fagnocchi, G; Bellini, E; Luoni, M; Cancellieri, C; Bagliani, A; Di Resta, C; Maffezzini, C; Ianielli, A; Ferrari, M; Piazza, R; Mologni, L; Broccoli, V; Sessa, A
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma
2021 Arosio, G; Sharma, G; Villa, M; Mauri, M; Crespiatico, I; Fontana, D; Manfroni, C; Mastini, C; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Massimino, L; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
Dual kinase targeting in leukemia
2021 Mologni, L; Marzaro, G; Redaelli, S; Zambon, A
Resistance mechanisms to ALK TKIs in tumors other than lung cancer
2021 Mologni, L
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer
2021 Villa, M; Sharma, G; Manfroni, C; Cortinovis, D; Mologni, L
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
2021 Larose, H; Prokoph, N; Matthews, J; Schlederer, M; Hogler, S; Alsulami, A; Ducray, S; Nuglozeh, E; Fazaludeen, M; Elmouna, A; Ceccon, M; Mologni, L; Gambacorti Passerini, C; Hoefler, G; Lobello, C; Pospisilova, S; Janikova, A; Woessmann, W; Damm-Welk, C; Zimmermann, M; Fedorova, A; Malone, A; Smith, O; Wasik, M; Inghirami, G; Lamant, L; Blundell, T; Klapper, W; Merkel, O; Amos Burke, G; Mian, S; Ashankyty, I; Kenner, L; Turner, S
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
2020 Crespiatico, I; Bossi, E; Brioschi, F; Piazza, R; Mologni, L; Gambacorti‐passerini, C
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
2020 Prokoph, N; Probst, N; Lee, L; Monahan, J; Matthews, J; Liang, H; Bahnsen, K; Montes-Mojarro, I; Karaca-Atabay, E; Sharma, G; Malik, V; Larose, H; Forde, S; Ducray, S; Lobello, C; Wang, Q; Luan, S; Pospisilova, S; Gambacorti Passerini, C; Burke, G; Pervez, S; Attarbaschi, A; Janikova, A; Pacquement, H; Landman-Parker, J; Lambilliotte, A; Schleiermacher, G; Klapper, W; Jauch, R; Woessmann, W; Vassal, G; Kenner, L; Merkel, O; Mologni, L; Chiarle, R; Brugieres, L; Geoerger, B; Barbieri, I; Turner, S
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
2020 Fontana, D; Ramazzotti, D; Aroldi, A; Redaelli, S; Magistroni, V; Pirola, A; Niro, A; Massimino, L; Mastini, C; Brambilla, V; Bombelli, S; Bungaro, S; Morotti, A; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Usala, E; Merli, M; Onida, F; Bregni, M; Elli, E; Fumagalli, M; Ciceri, F; Perego, R; Pagni, F; Mologni, L; Piazza, R; Gambacorti-Passerini, C
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
2019 Sharma, G; Cortinovis, D; Agustoni, F; Arosio, G; Villa, M; Cordani, N; Bidoli, P; Bisson, W; Pagni, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy
2019 Bossi, E; Brioschi, F; Steidl, C; Baretta, S; Cantu, S; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
We shall overcome (drug resistance) some day
2019 Geeta, G; Mologni, L
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
2019 Menotti, M; Ambrogio, C; Cheong, T; Pighi, C; Mota, I; Cassel, S; Compagno, M; Wang, Q; Dall’Olio, R; Minero, V; Poggio, T; Geeta, G; Patrucco, E; Mastini, C; Choudhari, R; Pich, A; Zamo, A; Piva, R; Giliani, S; Mologni, L; Collings, C; Kadoch, C; Gambacorti-Passerini, C; Notarangelo, L; Anton, I; Voena, C; Chiarle, R
Novel targeted therapeutics for MEN2
2018 Redaelli, S; Plaza-Menacho, I; Mologni, L
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells
2018 Mologni, L
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
2018 Ceccon, M; Mauri, M; Massimino, L; Giudici, G; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers
2018 Geeta, G; Redaelli, S; Ceccon, M; Zappa, M; Gambacorti-Passerini, C; Mologni, L
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile